Summary
Zoetis Inc. reported strong third-quarter results for 2023, with total revenue increasing by 7% to $2.15 billion, driven by an 8% operational increase. This growth was primarily fueled by price increases (approximately 5%) and volume growth from new products and key dermatology products. Net income attributable to Zoetis Inc. rose by 13% to $596 million, with diluted EPS increasing to $1.29 from $1.13 in the prior year period. The company demonstrated robust performance across both its U.S. and International segments, with companion animal products showing significant strength, particularly driven by their key dermatology portfolio and monoclonal antibody (mAb) products like Solensia and Librela. The company also highlighted a healthy increase in operating cash flow for the first nine months of 2023, reaching $1.46 billion, indicating strong cash generation. Strategic acquisitions, such as PetMedix and adivo, are being integrated, and the company continues to invest in research and development to support future innovation. Despite some headwinds from foreign exchange impacts and increased interest expenses, Zoetis maintains a solid financial position, supported by a well-managed debt structure and ample liquidity from its credit facilities.
Financial Highlights
51 data points| Revenue | $2.15B |
| Cost of Revenue | $638.00M |
| Gross Profit | $1.51B |
| SG&A Expenses | $525.00M |
| Interest Expense | $59.00M |
| Net Income | $596.00M |
| EPS (Basic) | $1.29 |
| EPS (Diluted) | $1.29 |
| Shares Outstanding (Basic) | 460.30M |
| Shares Outstanding (Diluted) | 461.40M |
Key Highlights
- 1Total revenue for Q3 2023 increased by 7% to $2.15 billion, with an 8% operational increase, driven by price and volume growth.
- 2Net income attributable to Zoetis Inc. grew by 13% to $596 million, and diluted EPS rose to $1.29 from $1.13 in Q3 2022.
- 3Companion animal products continue to be a strong performer, with key dermatology products and mAb offerings (Solensia, Librela) driving growth.
- 4U.S. segment revenue increased by 8% operationally, while the International segment saw an 8% operational revenue increase.
- 5Operating cash flow for the first nine months of 2023 was robust at $1.46 billion, up from $1.17 billion in the prior year period.
- 6The company completed two acquisitions in Q3 2023: PetMedix Ltd. and adivo GmbH, to expand its R&D capabilities.
- 7Zoetis maintained compliance with its financial covenants and had no amounts drawn under its $1 billion revolving credit facility as of September 30, 2023.